Warsaw Stock Exchange-listed Medicalgorithmics has launched its solution for a key U.S. client – one of the largest IDTFs by session volume – which has started using the company’s innovative DeepRhythmAI (DRAI) algorithms and DeepRhythm Platform (DRP) for commercial ECG study analysis.
The Management Board of Medicalgorithmics anticipates a dynamic increase in revenue from this contract, driven by the expected significant growth in the number of ECG sessions conducted by the U.S. partner.
Medicalgorithmics estimates that total revenue from this agreement – including both integration services and ongoing analysis of ECG sessions – will amount to approximately USD 7.7 million to USD 11.5 million over the first 24 months following acceptance of the integration and the start of commercial operations.
“The successful launch for one of the largest U.S. IDTFs marks a key milestone for Medicalgorithmics this year,” said Dr. Kris Siemionow, CEO of Medicalgorithmics. “Our American partner – who, according to market estimates, has annual growth potential of up to 50% – has commercially adopted our cutting-edge, highly efficient, and competitively positioned software. We expect that the planned increase in session volume, following a successful and satisfactory integration and client training phase, will accelerate our growth trajectory in the U.S. market and further boost our revenues.”
“In parallel, we are advancing integrations with additional clients and actively engaging new customers, including those in new geographic markets. We are effectively capitalizing on record-high interest in our best-in-class software,” Dr. Siemionow added.
The agreement, signed in January 2025, includes the provision of specified services and the licensing of Medicalgorithmics’ flagship DeepRhythm Platform (DRP), which incorporates proprietary DeepRhythmAI (DRAI) algorithms for ECG signal analysis using data collected from the partner’s diagnostic devices. Compensation, denominated in U.S. dollars, is usage-based and tied to the number of ECG sessions analyzed with the Polish medtech’s software each month. The contract also includes guaranteed minimum revenues – covering both integration and session analysis – exceeding USD 1.7 million.
Independent Diagnostic Testing Facilities (IDTFs), which operate outside of hospitals and other medical centers, play a critical role in the healthcare delivery ecosystem. The global market value of cardiac-focused IDTFs is projected at USD 8.24 billion in 2024, with a forecasted compound annual growth rate (CAGR) of 8.2% from 2025 to 2030 (ResearchAndMarkets.com).
The year 2025 has already brought a notable surge in demand for Medicalgorithmics’ solutions, along with accelerated client acquisition. Since the beginning of the year, the company has signed 13 new agreements – matching the total for all of 2024. These include contracts with one of the largest U.S. IDTFs, the first IDTF in Europe, and Cardioscan, a global leader in cardiac diagnostics.
Integration and validation phases with client infrastructure typically take 6 to 10 months post-contract signing, which positions the company to begin monetizing a portion of its newly signed agreements later this year.